ATM and neoplasm: Therefore, our results from three murine tumor models strongly suggested that anti-Gal-9 therapy combined with ATM inhibition significantly reduces tumor growth and enhances the survival of host mice, even in poorly immunogenic tumor models that are refractory to current immune checkpoint therapy.